TS2121422239	drug 45 74	sodium 2 , 2 dimethylbutyrate
TS421422239	drug 85 118	short chain fatty acid derivative
TS1521422239	drugEffect 398 438	increases in hemoglobin F ( HbF ) levels
TS1821422239	drugEffect 439 486	reduce clinical severity in sickle cell disease
TS321422239	sideeffect 506 512	anemia
TS821422239	treatedDisease 516 532	beta thalassemia
TS1021422239	drug 552 574	short chain fatty acid
TS221422239	drug 590 607	arginine butyrate
TS1621422239	drug 610 612	AB
TS1921422239	drug 621 635	phenylbutyrate
TS721422239	drugEffect 638 681	increased fetal and total hemoglobin levels
TS1721422239	drug 938 981	short chain fatty acids ( SCFA ) derivative
TS921422239	drug 984 1022	sodium 2 , 2 dimethylbutyrate ( SDMB )
TS1321422239	sideeffect 1643 1649	anemic
T1	treatedDisease 341 364	beta hemoglobinopathies
T2	treatedDisease 369 381	thalassemias
T3	drugEffect 499 512	reduce anemia
R1	has_effect Arg1:TS221422239 Arg2:TS721422239	
T4	modeadm 730 741	intravenous
T5	modeadm 744 746	IV
T6	modeadm 812 816	oral
T7	frequency 1043 1061	1 of 4 single dose
T8	dosage 1071 1097	2 , 5 , 10 , and 20 mg  kg
T9	frequency 1103 1114	daily doses
T10	dosage 1117 1138	5 , 10 , or 15 mg  kg
T11	duration 1141 1153	over 14 days
T12	drug 1262 1266	SDMB
T13	drug 1590 1594	SDMB
T14	treatedDisease 1664 1687	beta hemoglobinopathies
R2	treat Arg1:T13 Arg2:T14	
